Tags

Type your tag names separated by a space and hit enter

Curcumin: the story so far.
Eur J Cancer. 2005 Sep; 41(13):1955-68.EJ

Abstract

Curcumin is a polyphenol derived from the herbal remedy and dietary spice turmeric. It possesses diverse anti-inflammatory and anti-cancer properties following oral or topical administration. Apart from curcumin's potent antioxidant capacity at neutral and acidic pH, its mechanisms of action include inhibition of several cell signalling pathways at multiple levels, effects on cellular enzymes such as cyclooxygenase and glutathione S-transferases, immuno-modulation and effects on angiogenesis and cell-cell adhesion. Curcumin's ability to affect gene transcription and to induce apoptosis in preclinical models is likely to be of particular relevance to cancer chemoprevention and chemotherapy in patients. Although curcumin's low systemic bioavailability following oral dosing may limit access of sufficient concentrations for pharmacological effect in certain tissues, the attainment of biologically active levels in the gastrointestinal tract has been demonstrated in animals and humans. Sufficient data currently exist to advocate phase II clinical evaluation of oral curcumin in patients with invasive malignancy or pre-invasive lesions of the gastrointestinal tract, particularly the colon and rectum.

Authors+Show Affiliations

Cancer Biomarkers and Prevention Group, Department of Cancer Studies and Molecular Medicine, University of Leicester, Leicester Royal Infirmary, Leicester LE2 7LX, UK. ras20@le.ac.ukNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

16081279

Citation

Sharma, R A., et al. "Curcumin: the Story so Far." European Journal of Cancer (Oxford, England : 1990), vol. 41, no. 13, 2005, pp. 1955-68.
Sharma RA, Gescher AJ, Steward WP. Curcumin: the story so far. Eur J Cancer. 2005;41(13):1955-68.
Sharma, R. A., Gescher, A. J., & Steward, W. P. (2005). Curcumin: the story so far. European Journal of Cancer (Oxford, England : 1990), 41(13), 1955-68.
Sharma RA, Gescher AJ, Steward WP. Curcumin: the Story so Far. Eur J Cancer. 2005;41(13):1955-68. PubMed PMID: 16081279.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Curcumin: the story so far. AU - Sharma,R A, AU - Gescher,A J, AU - Steward,W P, PY - 2005/03/15/received PY - 2005/05/13/accepted PY - 2005/8/6/pubmed PY - 2005/12/13/medline PY - 2005/8/6/entrez SP - 1955 EP - 68 JF - European journal of cancer (Oxford, England : 1990) JO - Eur J Cancer VL - 41 IS - 13 N2 - Curcumin is a polyphenol derived from the herbal remedy and dietary spice turmeric. It possesses diverse anti-inflammatory and anti-cancer properties following oral or topical administration. Apart from curcumin's potent antioxidant capacity at neutral and acidic pH, its mechanisms of action include inhibition of several cell signalling pathways at multiple levels, effects on cellular enzymes such as cyclooxygenase and glutathione S-transferases, immuno-modulation and effects on angiogenesis and cell-cell adhesion. Curcumin's ability to affect gene transcription and to induce apoptosis in preclinical models is likely to be of particular relevance to cancer chemoprevention and chemotherapy in patients. Although curcumin's low systemic bioavailability following oral dosing may limit access of sufficient concentrations for pharmacological effect in certain tissues, the attainment of biologically active levels in the gastrointestinal tract has been demonstrated in animals and humans. Sufficient data currently exist to advocate phase II clinical evaluation of oral curcumin in patients with invasive malignancy or pre-invasive lesions of the gastrointestinal tract, particularly the colon and rectum. SN - 0959-8049 UR - https://www.unboundmedicine.com/medline/citation/16081279/Curcumin:_the_story_so_far_ DB - PRIME DP - Unbound Medicine ER -